Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 128,231 | 5,678 | 231 | 7,319 | 5,130 |
Gross Profit | 128,231 | 5,678 | 231 | 7,319 | 5,130 |
Operating Expenses | 59,531 | 54,939 | 50,087 | 53,952 | 50,038 |
Operating Income | 68,700 | -49,261 | -49,856 | -46,633 | -44,908 |
Interest Expense | 526 | 0 | 0 | 0 | 0 |
Other Income | 1,873 | 1,284 | 1,283 | 1,719 | 24,199 |
Pre-tax Income | 70,047 | -47,977 | -48,573 | -44,914 | -20,709 |
Income Tax | 526 | 526 | -656 | 687 | 680 |
Net Income Continuous | 69,521 | -48,503 | -47,917 | -45,601 | -21,389 |
Net Income | $69,521 | $-48,503 | $-47,917 | $-45,601 | $-21,389 |
EPS Basic Total Ops | 0.30 | -0.20 | -0.22 | -0.20 | -0.12 |
EPS Basic Continuous Ops | 0.27 | -0.20 | -0.26 | -0.20 | -0.12 |
EPS Diluted Total Ops | 0.24 | -0.20 | -0.22 | -0.20 | -0.12 |
EPS Diluted Continuous Ops | 0.27 | -0.20 | -0.26 | -0.20 | -0.12 |
EPS Diluted Before Non-Recurring Items | 0.27 | -0.18 | -0.24 | -0.20 | -0.21 |
EBITDA(a) | $71,442 | $-46,431 | $-46,985 | $-43,741 | $-42,676 |